FAKTOR OPTIONSSCHEIN - GENMAB | Market Closed - Boerse Frankfurt Warrants 10:21:05 2024-06-14 EDT | ||
| 4.49 EUR | +0.90% |
|
| Current month | -21.91% | ||
| 1 month | -36.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 4.49 | +0.90% |
| 24-06-13 | 4.45 | -5.92% |
| 24-06-12 | 4.73 | -7.07% |
| 24-06-11 | 5.09 | -6.26% |
| 24-06-10 | 5.43 | -0.73% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 10:21 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PE4GEN |
| ISIN | DE000PE4GEN0 |
| Date issued | 2022-03-11 |
| Strike | 1,824 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 146 € |
|---|---|
| Lowest since issue | 4.35 € |
| Spread | 0.02 € |
| Spread % | 0.44% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
- Stock Market
- Certificates
- Certificat
